Atorvastatin to lower liver cancer risk in people with liver scarring
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign informed consent and follow the study plan
- Be age 18 or older
- Have advanced liver scarring or cirrhosis confirmed by tests or imaging
- Have higher-than-average risk for liver cancer based on blood scores (FIB-4 and PLSec)
- Have recent liver imaging (if you already have cirrhosis) to make sure cancer is not already present
- Be willing to have frequent blood tests and take the study pills as instructed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug rosuvastatin, a cholesterol-lowering medicine, can improve liver health in people with cirrhosis. If you have compensated cirrhosis (no recent serious liver problems), you might be able to join.
This trial tests if adding a statin to beta blocker treatment helps people with advanced liver disease (cirrhosis) who have had complications like fluid buildup, confusion, or bleeding. It is for patients who are already taking a non-selective beta blocker and will be followed for 12 months.
This study is testing ways to prevent and treat liver scarring (fibrosis) caused by a condition called MAFLD, which is a buildup of fat in the liver. If you have this condition and some liver scarring, this trial may offer a chance to help manage it.
This study compares ultrasound scans versus MRI scans to see which one better helps prevent deaths from liver cancer in people with cirrhosis. You may be assigned to one of the two imaging tests and follow-up visits to track whether liver cancer develops or is caught early.
This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.
This trial is testing whether taking a low dose of aspirin every day can lower the risk of developing liver cancer (hepatocellular carcinoma, or HCC) in people with liver cirrhosis. Liver cirrhosis is scarring of the liver, and having it increases the risk of liver cancer. If you are eligible, you would be asked to take aspirin or a placebo (a pill with no active medicine) and have regular check-ups to see if aspirin helps prevent cancer.
Hear when a new Liver Fibroses trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.